



Docket No. ORT 1222 (DIV)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : McComsey et al

Serial No. : 10/606,422

Art Unit: 1653

Filed : JUNE 26, 2003

Examiner: LUKTON, DAVID

For : SUBSTITUTED HETEROCYCLIC ACYL-TRIPEPTIDES USEFUL AS  
THROMBIN RECEPTOR MODULATORS

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

NOVEMBER 2, 2006

(Date of Deposit)

YURIY P. STERCHO, PH.D.

(Name of applicant, assignee, or Registered Representative)

(Signature)

NOVEMBER 2, 2006

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement filed on January 15, 2005 and the First Supplemental Information Disclosure Statement filed on February 10, 2006.

The Examiner did not consider two references cited in the First Supplemental IDS, specifically Derian, C. et al., "Vascular Occlusion in Non-Human Primates" and Mouse, S., "Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonist and beyond."

Applicants herewith submit these references for consideration by the Examiner.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified

application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached);  
or
- ☐ Please charge Deposit Account No. 10-0750/ORT1222(DIV)/YS the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final

Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached);  
or
- ☐ Please charge Deposit Account No. 10-  
0750/ORT1222(DIV)/YS the fee of \$180.00 as set  
forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

☐ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:


☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1222(DIV)/YS. This form is submitted in triplicate.

Respectfully submitted,

  
YURIY P. STERCHO, PH.D.  
Reg. No. 33,797  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(610) 240-8006  
DATED: NOVEMBER 2, 2006

<b>Application Number</b>	10/606,422
<b>Filing Date</b>	June 26, 2003
<b>First Named Inventor</b>	McComsey
<b>Group Art Unit</b>	1653
<b>Examiner Name</b>	LUKTON, DAVID
<b>Attorney Docket Number</b>	ORT 1222(DIV)